Eur J Pharmacol:补骨脂二氢黄酮甲醚Bavachinin可作为抑制肿瘤血管生成的治疗剂

2012-07-10 Beyond 生物谷

缺氧诱导因子1(HIF-1)有两个亚基,在缺氧情况下,HIF-1α会过度表达,HIF-1α转录活性的增加与肿瘤进展、血管生成、转移和侵袭密切相关。 近日European Journal of Pharmacology杂志上的一则研究证实天然化合物补骨脂二氢黄酮甲醚 Bavachinin在体外和体内有较强的抗血管生成活性。Bavachinin浓度依赖性抑制人KB癌(HeLa细胞的衍生细胞株)HIF

缺氧诱导因子1(HIF-1)有两个亚基,在缺氧情况下,HIF-1α会过度表达,HIF-1α转录活性的增加与肿瘤进展、血管生成、转移和侵袭密切相关。

近日European Journal of Pharmacology杂志上的一则研究证实天然化合物补骨脂二氢黄酮甲醚 Bavachinin在体外和体内有较强的抗血管生成活性。Bavachinin浓度依赖性抑制人KB癌(HeLa细胞的衍生细胞株)HIF-1α活性,其机制是通过促进(VHL)与HIF-1α之间的相互作用。

此外,Bavachinin降低与血管生成和能量代谢相关基因的表达如血管内皮生长因子(VEGF)、Glut1和己糖激酶2。Bavachinin也抑制人类脐静脉内皮细胞(内皮细胞)的管腔形成以及KB细胞在体外的迁移能力。体内研究显示,给予KB移植瘤裸鼠每周三次注射Bavachinin,共持续四星期能显著减少肿瘤体积和CD31的表达。这些数据表明Bavachinin可以作为抑制肿瘤血管生成的治疗剂。


doi:10.1016/j.ejphar.2012.06.028
PMC:
PMID:

Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α

Manoj Nepala, b, Hwa Jung Choia, Bo-Yun Choia, b, Se Lim Kima, Jae-Ha Ryuc, Ho Hee Kimc, Young-Hoon Leed, Yunjo Soha,

Hypoxia-inducible factor-1 (HIF-1) consists of two subunits, the HIF-1β, which is constitutively expressed, and HIF-1α, which is oxygen-responsive. HIF-1α is over-expressed in response to hypoxia, increasing transcriptional activity linked to tumor progression, angiogenesis, metastasis, and invasion. This study aimed to demonstrate that the natural compound, Bavachinin, has potent anti-angiogenic activity in vitro and in vivo. Bavachinin inhibited increases in HIF-1α activity in human KB carcinoma (HeLa cell derivative) and human HOS osteosarcoma cells under hypoxia in a concentration-dependent manner, probably by enhancing the interaction between von Hippel–Lindau (VHL) and HIF-1α. Furthermore, Bavachinin decreased transcription of genes associated with angiogenesis and energy metabolism that are regulated by HIF-1, such as vascular endothelial growth factors (VEGF), Glut 1 and Hexokinase 2. Bavachinin also inhibited tube formation in human umbilical vein endothelial cells (HUVECs) as well as in vitro migration of KB cells. In vivo studies showed that injecting Bavachinin thrice weekly for four weeks significantly reduced tumor volume and CD31 expression in nude mice with KB xenografts. These data indicate that Bavachinin could be used as a therapeutic agent for inhibiting tumor angiogenesis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2017-06-09 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2013-04-26 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2013-04-14 fengyi821
  6. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2013-04-07 yb6560
  10. [GetPortalCommentsPageByObjectIdResponse(id=208726, encodeId=9828208e26cb, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 09 22:46:09 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787120, encodeId=fdd31e871207d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 26 04:07:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788138, encodeId=0de71e88138d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Apr 20 21:07:00 CST 2013, time=2013-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040902, encodeId=bea72040902ea, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Thu Nov 29 00:07:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683551, encodeId=b278168355162, content=<a href='/topic/show?id=3f17103210ed' target=_blank style='color:#2F92EE;'>#黄酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103210, encryptionId=3f17103210ed, topicName=黄酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443c27982006, createdName=fengyi821, createdTime=Sun Apr 14 15:07:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076639, encodeId=ccbf20e66391a, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Aug 26 08:07:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809223, encodeId=89fa180922328, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Sep 09 23:07:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812738, encodeId=808a1812e3859, content=<a href='/topic/show?id=938e9019264' target=_blank style='color:#2F92EE;'>#补骨脂二氢黄酮甲醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90192, encryptionId=938e9019264, topicName=补骨脂二氢黄酮甲醚)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 22 11:07:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995874, encodeId=8c8b19958e49e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Apr 07 10:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908147, encodeId=6640190814e6b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Dec 22 16:07:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]

相关资讯

Eur Heart J:房颤者中断用华法林 血栓栓塞风险升高

12月23日,丹麦学者在Eur Heart J发表的一项研究"Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation"表明,在房颤患者中,中断华法林治疗与治疗中断后前90天内的死亡或血栓-栓